PUBLIC COMPANY
save$MPLTMapLight Therapeutics, Inc.
$MPLT7.6300+2.55%Redwood City, CA, USupdated 5d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- phase2An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
- phase2A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- phase2ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
- phase2A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
- phase2ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
🐶 Hiring Signal
News
- Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.biospace · 1d ago
- Forbion, a prominent biotech investor, raises $2.6B for a pair of venture fundsThe fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.biopharma_dive · 1mo ago
- As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the doorDespite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…biospace · 3mo ago
- MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 winMapLight Therapeutics’ stock {$MPLT} plummeted more than 60% on Monday after a once-daily regimen of its schizophrenia drug missed the primary endpoint in a mid-stage trial, despite the study’s ove…endpoints · 3mo ago
- MapLight’s schizophrenia drug dampens once-daily hopes despite Phase 2 winMapLight Therapeutics’ stock {$MPLT} plummeted more than 60% on Monday after a once-daily regimen of its schizophrenia drug missed the primary endpoint in a mid-stage trial, despite the study’s ove…endpoints · 3mo ago
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that